AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
12min chapter
What are the pros and cons of bispecific antibodies for multiple myeloma?
Multiple Myeloma Hub
Advancements in Bi-Specific Antibodies for Multiple Myeloma
A comprehensive overview of the effectiveness and challenges of bi-specific antibodies targeting agents like BCMA, Tolketamab, and Sivostamab, showcasing promising results comparable to CAR-T therapy. The chapter delves into implications, patient response rates, safety profiles, challenges in drug delivery, and direct comparisons with CAR-T therapies.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode